Latest Earnings Results: Q3 '26
Estimated EPS
-$0.56
Reported EPS
-$0.37
Surprise
+34.27%
Estimated Rev
$0M
Reported Rev
---
Surprise
---
Definium Therapeutics reported Q3 2026 research and development expenses of $46.1M and general and administrative expenses of $26.1M; net loss was $51M, or $0.37 basic per share.
Generated by Stocktwits using AI and company-reported earnings data for Q3 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q4 '26 | -$0.50 | -- | -- | N/A |
Q3 '26 | -$0.56 | -$0.37 | 34.27% | BEAT |
Q2 '26 | -$0.54 | -$1.44 | -166.19% | MISSED |
Q1 '26 | -$0.49 | -$0.71 | -44.27% | MISSED |
Q4 '25 | -$0.48 | -$0.51 | -5.44% | MISSED |